MacroGenics has seen its share price plummet after Phase II results of its antibody-drug conjugate (ADC) showed a worsening safety profile in metastatic castration-resistant prostate cancer patients, including three as-yet unexplained deaths.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?